ASRT Assertio Holdings Inc.

Assertio Holdings, Inc. to Host Investor and Business Development Meetings January 9-11, 2023 in San Francisco

Assertio Holdings, Inc. to Host Investor and Business Development Meetings January 9-11, 2023 in San Francisco

Meetings to Take Place Adjacent to JP Morgan Healthcare Conference

LAKE FOREST, Ill., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced that its executive team will host one-on-one investor and business development meetings in San Francisco January 9-11, 2023. The individual meetings will take place at the same time as the annual JP Morgan Healthcare Conference.

For more information and to schedule an investor meeting, please contact Matt Kreps, investor relations for Assertio, at . To arrange a business development meeting, please contact Vanessa Fox, Vice President, Business Development and Commercial Analytics for Assertio, at .

About Assertio

Assertio is a specialty pharmaceutical company offering differentiated products to patients utilizing a non-personal promotional model. We have built and continue to build our commercial portfolio by identifying new opportunities within our existing products as well as acquisitions or licensing of additional approved products. To learn more visit .

Investor Contact:

Matt Kreps

Managing Director

Darrow Associates

M: 214-597-8200



EN
13/12/2022

Underlying

ASRTAssertio Holdings Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Assertio Holdings Inc.

 PRESS RELEASE
Free
ASRT Assertio Holdin...

Assertio Presents First-Ever Real-World Study Showing Patient Experien...

Assertio Presents First-Ever Real-World Study Showing Patient Experience with SYMPAZAN® (clobazam) Oral Film, CIV New data show how Sympazan is being used in daily clinical practice to treat patients with Lennox-Gastaut Syndrome (LGS), a severe form of childhood-onset epilepsyStudy addresses lack of awareness and real-world data with oral film formulation of clobazamNew data presented during poster session at 150th Annual Meeting of the American Neurological AssociationSYMPAZAN is the only FDA-approved oral film formulation of clobazam for adjunctive treatment of seizures associated with LG...

September 15, 2025 1 EN
 PRESS RELEASE
Free
ASRT Assertio Holdin...

Assertio to Present New Data from Real-World Evidence Study of SYMPAZA...

Assertio to Present New Data from Real-World Evidence Study of SYMPAZAN® at upcoming 150th Annual Meeting of the American Neurological Association Poster presentation will feature new data for SYMPAZAN, the only FDA-approved oral film formulation of clobazam for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in patients two years of age or olderAbstract is now available on ANA2025 website LAKE FOREST, Ill., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commerci...

September 10, 2025 1 EN
 PRESS RELEASE
Free
ASRT Assertio Holdin...

Assertio to Participate in the HC Wainwright and Lake Street Conferenc...

Assertio to Participate in the HC Wainwright and Lake Street Conferences in September 2025 LAKE FOREST, Ill., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT) announced that members of its management team will host investor meetings at two investor conferences in New York City during September 2025. Company management will host investor meetings at the HC Wainwright Conference on Wednesday, September 10, 2025, taking place at the Lotte New York Palace Hotel. Investors can register and request meetings via their HC Wainwright repr...

September 3, 2025 1 EN
 PRESS RELEASE
Free
ASRT Assertio Holdin...

Assertio Reports Second Quarter 2025 Financial Results

Assertio Reports Second Quarter 2025 Financial Results Second Quarter Total Net Product Sales of $28.8 Million, Cash and Investments Increase to $98.2 Million Narrows Guidance on Continued Progress Implementing Long-Term Business Strategy LAKE FOREST, Ill., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products designed to address patients’ needs, today reported financial results for the second quarter ended June 30, 2025. Said Brendan O...

August 11, 2025 1 EN
 PRESS RELEASE
Free
ASRT Assertio Holdin...

Assertio Holdings, Inc. to Report Second Quarter 2025 Financial Result...

Assertio Holdings, Inc. to Report Second Quarter 2025 Financial Results on August 11, 2025 LAKE FOREST, Ill., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT) today announced that it will release second quarter 2025 financial results on Monday, August 11, 2025, after the market close. Additionally, Assertio’s management will host a live webcast conference call at 4:30 p.m. Eastern Time to discuss the financial results and provide business updates on the Company’s 2025 strategic plans. To access the live webcast, conference call inform...

August 5, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch